(NASDAQ: GLSI) Greenwich Lifesciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.18%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.16%.
Greenwich Lifesciences's earnings in 2025 is -$17,992,572.On average, 4 Wall Street analysts forecast GLSI's earnings for 2025 to be -$15,223,634, with the lowest GLSI earnings forecast at -$16,697,065, and the highest GLSI earnings forecast at -$13,453,064. On average, 3 Wall Street analysts forecast GLSI's earnings for 2026 to be -$20,576,236, with the lowest GLSI earnings forecast at -$19,769,325, and the highest GLSI earnings forecast at -$21,181,419. 
In 2027, GLSI is forecast to generate -$20,437,207 in earnings, with the lowest earnings forecast at -$19,635,748 and the highest earnings forecast at -$21,038,302.